These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K; J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224 [TBL] [Abstract][Full Text] [Related]
6. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005 [TBL] [Abstract][Full Text] [Related]
7. A benefit-risk assessment of sibutramine in the management of obesity. Nisoli E; Carruba MO Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064 [TBL] [Abstract][Full Text] [Related]
8. Sibutramine. A review of its contribution to the management of obesity. McNeely W; Goa KL Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996 [TBL] [Abstract][Full Text] [Related]
9. The discovery and status of sibutramine as an anti-obesity drug. Luque CA; Rey JA Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530 [TBL] [Abstract][Full Text] [Related]
10. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522 [TBL] [Abstract][Full Text] [Related]
11. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Seagle HM; Bessesen DH; Hill JO Obes Res; 1998 Mar; 6(2):115-21. PubMed ID: 9545017 [TBL] [Abstract][Full Text] [Related]
12. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Van Gaal LF; Wauters MA; De Leeuw IH Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480 [TBL] [Abstract][Full Text] [Related]
13. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Nisoli E; Carruba MO Obes Rev; 2000 Oct; 1(2):127-39. PubMed ID: 12119986 [TBL] [Abstract][Full Text] [Related]
14. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Luque CA; Rey JA Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502 [TBL] [Abstract][Full Text] [Related]
15. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ; Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325 [TBL] [Abstract][Full Text] [Related]
16. Modern medical management of obesity: the role of pharmaceutical intervention. Aronne LJ J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732 [TBL] [Abstract][Full Text] [Related]
17. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP; Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597 [TBL] [Abstract][Full Text] [Related]
19. Sibutramine--a review of clinical efficacy. Lean ME Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039 [TBL] [Abstract][Full Text] [Related]
20. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]